Literature DB >> 16344954

[Necrosis of the jaws under bisphosphonate therapy].

S Hoefert1, H Eufinger.   

Abstract

Bisphosphonates are widely used in the treatment of cancer patients with hypercalcemia and bone metastases or in osteoporosis therapy. Current reports have focused on therapy-resistant osteonecrosis of the jaws as a possible side effect of bisphosphonates. Official German drug committees have recently warned about the possibility of these side effects. So far we have experience with 12 patients showing therapy-resistant osteonecrosis of the mandible under bisphosphonate medication, three of whom received oral bisphosphonates for osteoporosis treatment. Presentation of these three cases provides more information on this clinically important side effect of oral bisphosphonate medication, also in osteoporosis therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16344954     DOI: 10.1007/s00132-005-0901-y

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  20 in total

1.  Intravenous bisphosphonates and osteonecrosis.

Authors:  Martin S Greenberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-09

2.  Bisphosphanates and oral cavity avascular bone necrosis.

Authors:  Cesar A Migliorati
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

3.  Bis-phossy jaw, phossy jaw, and the 21st century: bisphosphonate-associated complications of the jaws.

Authors:  John W Hellstein; Cindy L Marek
Journal:  J Oral Maxillofac Surg       Date:  2004-12       Impact factor: 1.895

4.  Bisphosphonates and avascular necrosis of the jaw: a possible association.

Authors:  Glen Carter; Alastair N Goss; Chris Doecke
Journal:  Med J Aust       Date:  2005-04-18       Impact factor: 7.738

5.  Bisphosphonates and osteonecrosis of the jaw.

Authors:  Patrick M Purcell; Ian W Boyd
Journal:  Med J Aust       Date:  2005-04-18       Impact factor: 7.738

6.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

7.  Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.

Authors:  L I Plotkin; R S Weinstein; A M Parfitt; P K Roberson; S C Manolagas; T Bellido
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 8.  Bisphosphonates--a word of caution.

Authors:  N A Robinson; J F Yeo
Journal:  Ann Acad Med Singapore       Date:  2004-07       Impact factor: 2.473

9.  Treatment of monostotic fibrous dysplasia with pamidronate.

Authors:  Marcin Kos; Klaudiusz Luczak; Jan Godzinski; Jan Klempous
Journal:  J Craniomaxillofac Surg       Date:  2004-02       Impact factor: 2.078

10.  Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.

Authors:  J S Day; M Ding; P Bednarz; J C van der Linden; T Mashiba; T Hirano; C C Johnston; D B Burr; I Hvid; D R Sumner; H Weinans
Journal:  J Orthop Res       Date:  2004-05       Impact factor: 3.494

View more
  2 in total

1.  Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.

Authors:  Sebastian Hoefert; Inge Schmitz; Andrea Tannapfel; Harald Eufinger
Journal:  Clin Oral Investig       Date:  2009-06-18       Impact factor: 3.573

Review 2.  Osteonecrosis of the jaw.

Authors:  Philip N Sambrook; Peter Ebeling
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.